CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | caffeic acid |
|
Accession: | CHEBI:36281
|
browse the term
|
Definition: | A hydroxycinnamic acid that is cinnamic acid in which the phenyl ring is substituted by hydroxy groups at positions 3 and 4. It exists in cis and trans forms; the latter is the more common. |
Synonyms: | exact_synonym: | 3-(3,4-dihydroxyphenyl)prop-2-enoic acid |
| related_synonym: | Formula=C9H8O4; InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13); InChIKey=QAIPRVGONGVQAS-UHFFFAOYSA-N; SMILES=OC(=O)C=Cc1ccc(O)c(O)c1 |
| xref: | Beilstein:2210883; HMDB:HMDB0001964; KEGG:C01481; LINCS:LSM-5272; PMID:11373473; PMID:15778121; PMID:18061431; PMID:18314336; PMID:18482095; PMID:20542693; PMID:8340025; Reaxys:2210883 |
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
acteoside results in decreased expression of ACTA2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases expression |
ISO |
acteoside results in decreased expression of AGER protein |
CTD |
PMID:33522686 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases localization |
ISO |
acteoside promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] acteoside results in decreased localization of AHR protein |
CTD |
PMID:21756928 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
acteoside results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions decreases secretion |
ISO |
acteoside results in decreased expression of CCL2 mRNA acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] acteoside results in decreased secretion of CCL2 protein |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCNE1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
acteoside results in increased expression of CDH1 protein |
CTD |
PMID:33522686 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
acteoside results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions |
ISO |
acteoside results in decreased activity of CDK4 protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein]; acteoside results in decreased expression of and results in decreased activity of CDK6 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1A mRNA; acteoside results in increased expression of CDKN1A protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1B mRNA; acteoside results in increased expression of CDKN1B protein acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases secretion decreases expression multiple interactions |
ISO |
acteoside results in decreased secretion of CXCL10 protein acteoside results in decreased expression of CXCL10 mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
acteoside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
acteoside inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:14672760 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of EGFR protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression |
ISO |
acteoside results in decreased expression of HMGB1 protein |
CTD |
PMID:33522686 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of ICAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of IFNG mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21371465 PMID:21756928 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] acteoside results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein] |
CTD |
PMID:16393473 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of MAPK1 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] acteoside results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO |
acteoside results in decreased phosphorylation of MAPK3 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] acteoside results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nox1 |
NADPH oxidase 1 |
decreases activity |
ISO |
acteoside results in decreased activity of NOX1 protein |
CTD |
PMID:16393473 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects binding |
ISO |
acteoside binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[acteoside co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
Verbascoside decreases expression of RAC1 mRNA in colon cancer cells |
RGD |
PMID:29886834 |
RGD:153298971 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of RB1 protein [acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of RELA protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] acteoside results in decreased phosphorylation of RELA protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD2 protein |
CTD |
PMID:17634406 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
acteoside results in increased expression of SMAD7 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI2 protein |
CTD |
PMID:33522686 |
|
NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SOD2 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
acteoside results in increased expression of TGFB1 mRNA |
CTD |
PMID:17634406 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of VCAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of ACHE protein |
CTD |
PMID:20854806 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of ACLY mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:23146752 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Alb |
albumin |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] Chlorogenic Acid affects the reaction [2,2'-azobis(2-amidinopropane) results in increased degradation of ALB protein] |
CTD |
PMID:11322927 PMID:23146752 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of AR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF4 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of ATF6 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF6 protein] |
CTD |
PMID:34801538 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI protein] |
CTD |
PMID:23146752 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of BAX mRNA] Chlorogenic Acid results in increased expression of BAX mRNA; Chlorogenic Acid results in increased expression of BAX protein Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:28623112 PMID:33058431 PMID:33242462 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] Chlorogenic Acid results in decreased expression of BCL2 mRNA; Chlorogenic Acid results in decreased expression of BCL2 protein Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of BCL2 mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:33058431 PMID:33242462 PMID:34801538 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Canx |
calnexin |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of CANX protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CANX protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CASP12 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein] Chlorogenic Acid results in increased expression of CASP3 mRNA Chlorogenic Acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP3 protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:33058431 PMID:33242462 PMID:34801538 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased expression of CASP8 protein] |
CTD |
PMID:28623112 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP9 protein] |
CTD |
PMID:28479099 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of CAT protein] Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of CAT mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 PMID:33242462 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CCL2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:26079055 PMID:31306686 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CCND1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CD44 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CDH1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of COL1A1 mRNA Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] |
CTD |
PMID:20706672 PMID:23146752 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cs |
citrate synthase |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of CS protein |
CTD |
PMID:31306686 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CXCL1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CXCL1 protein] |
CTD |
PMID:26079055 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cygb |
cytoglobin |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of CYGB mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of CYP19A1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of DDIT3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of DDIT3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dsg3 |
desmoglein 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of DSG3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:11,798,905...11,833,415
Ensembl chr18:11,798,900...11,830,818
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of EGF mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of EIF2AK3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of ERN1 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ERO1A protein] |
CTD |
PMID:34801538 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
EXP |
Chlorogenic Acid results in decreased expression of ESR1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of ESR2 protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F10 protein |
CTD |
PMID:27704645 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F2 protein |
CTD |
PMID:27704645 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbn1 |
fibrillin 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbn2 |
fibrillin 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:51,499,737...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of FGF1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of FSHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of FSHR protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of GCLC mRNA Chlorogenic Acid promotes the reaction [Acetaminophen results in increased expression of GCLC mRNA] |
CTD |
PMID:29136249 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GCLM mRNA |
CTD |
PMID:29136249 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions decreases expression |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased activity of GPT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] Chlorogenic Acid results in decreased expression of GPT protein Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased activity of GPT protein] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 PMID:33058431 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grn |
granulin precursor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GRN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of GSR protein] Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GSR mRNA] |
CTD |
PMID:28479099 PMID:33242462 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of GSTA1 protein |
CTD |
PMID:15944151 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HAS1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression |
EXP ISO |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] Chlorogenic Acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:20696151 PMID:21870829 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein] Chlorogenic Acid results in increased expression of HMOX1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein] |
CTD |
PMID:25043994 PMID:29136249 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of HSPA5 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of HSPA5 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HSPB1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of IL1A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] |
CTD |
PMID:23146752 PMID:24709313 PMID:26079055 PMID:33242462 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of IL6 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:26079055 PMID:31390532 PMID:33242462 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
EXP |
Chlorogenic Acid results in decreased expression of ITGB2 protein Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of ITGB2 protein] |
CTD |
PMID:21414398 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of JUN protein] |
CTD |
PMID:15944151 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Krt5 |
keratin 5 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of KRT5 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 7:132,846,355...132,851,986
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] |
CTD |
PMID:20696151 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of LHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] |
CTD |
PMID:20696151 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAP2K4 protein] |
CTD |
PMID:15944151 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:15944151 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34801538 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mc1r |
melanocortin 1 receptor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of MC1R mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:51,452,448...51,455,375
Ensembl chr19:51,453,239...51,454,192
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Chlorogenic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MPO protein] |
CTD |
PMID:26079055 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of COX1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Zymosan] results in decreased expression of COX2 protein; Chlorogenic Acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MYD88 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization multiple interactions increases response to substance affects localization decreases response to substance |
ISO |
Chlorogenic Acid results in increased localization of NFE2L2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein]; [Chlorogenic Acid co-treated with Acetaminophen] results in increased activity of and affects the localization of NFE2L2 protein; [Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein; U 0126 inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] [Chlorogenic Acid co-treated with Acetaminophen] affects the localization of and results in increased activity of NFE2L2 protein; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA] NFE2L2 results in increased susceptibility to Chlorogenic Acid Chlorogenic Acid affects the localization of NFE2L2 protein NFE2L2 gene mutant form results in decreased susceptibility to Chlorogenic Acid |
CTD |
PMID:15944151 PMID:29136249 PMID:33242462 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20026373 PMID:23146752 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of NFKBIB protein] |
CTD |
PMID:20026373 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of NOS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:28479099 PMID:31306686 PMID:33242462 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of NOS3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Fructose] results in increased expression of NPPB protein] |
CTD |
PMID:34801538 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased activity of NQO1 protein Chlorogenic Acid results in increased expression of NQO1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN protein] |
CTD |
PMID:31390532 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of P4HB protein] |
CTD |
PMID:34801538 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Chlorogenic Acid promotes the reaction [Cisplatin results in increased expression of PCNA protein] |
CTD |
PMID:25043994 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PECAM1 protein] |
CTD |
PMID:21414398 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pgr |
progesterone receptor |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PGR mRNA Chlorogenic Acid results in decreased expression of PGR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of PIK3R1 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of PLOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PPARG mRNA Chlorogenic Acid results in decreased expression of PPARG mRNA |
CTD |
PMID:20706672 PMID:21870829 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP2R1A protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP5C protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein] Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of and results in increased expression of PTGS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:25043994 PMID:28479099 PMID:31306686 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RAD23A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of RARA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of and results in increased phosphorylation of and affects the localization of RELA protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein] |
CTD |
PMID:20026373 PMID:26079055 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retreg1 |
reticulophagy regulator 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of RETREG1 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:76,335,609...76,474,817
Ensembl chr 2:76,335,609...76,493,898
|
|
G |
Rtn3 |
reticulon 3 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of RTN3 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275
|
|
G |
Rxra |
retinoid X receptor alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RXRA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sec62 |
SEC62 homolog, preprotein translocation factor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of SEC62 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 2:112,570,810...112,607,576
Ensembl chr 2:112,570,819...112,601,814
|
|
G |
Sell |
selectin L |
multiple interactions |
EXP |
[Chlorogenic Acid co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of SELL protein; Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of SELL protein] |
CTD |
PMID:21414398 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in decreased expression of SLC22A2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of SOD2 mRNA Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of SQSTM1 protein] |
CTD |
PMID:29136249 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of STAR protein |
CTD |
PMID:29899696 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR3 protein] |
CTD |
PMID:26079055 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR4 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of TNF mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:25043994 PMID:26079055 PMID:31306686 PMID:31390532 PMID:33242462 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TRP53 protein] Chlorogenic Acid results in increased expression of TRP53 mRNA |
CTD |
PMID:25043994 PMID:33058431 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TPT1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of TRAF2 protein] |
CTD |
PMID:34801538 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TXN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of Chlorogenic Acid [TYR protein results in increased oxidation of Chlorogenic Acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of TYRP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Chlorogenic Acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of XBP1 mRNA] |
CTD |
PMID:34801538 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
caffeic acid results in increased phosphorylation of and results in decreased activity of ACACA protein |
CTD |
PMID:28576465 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of ACHE protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of ACHE protein] |
CTD |
PMID:28465162 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein |
CTD |
PMID:28576465 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions decreases activity |
ISO |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein]; [caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; caffeic acid inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of ALOX15 protein] |
CTD |
PMID:10904086 PMID:11406566 PMID:15574791 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]; caffeic acid inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein] caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 protein] |
CTD |
PMID:18482095 PMID:18951527 PMID:27368151 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein modified form]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein] |
CTD |
PMID:18482095 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
decreases activity |
ISO |
caffeic acid results in decreased activity of ARG1 protein |
CTD |
PMID:27378625 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ATP6V0D2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein] caffeic acid inhibits the reaction [Valproic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:15574791 PMID:29968957 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; caffeic acid inhibits the reaction [Nickel results in decreased activity of CAT protein] caffeic acid results in increased activity of CAT protein caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CAT protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] |
CTD |
PMID:18405891 PMID:21640567 PMID:22036979 PMID:27378625 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL2 mRNA; caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:16806235 PMID:31306686 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL3 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR2 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:114,176,256...114,182,155
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 4:157,668,878...157,695,366
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD68 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of CDC20 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of CDK2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in decreased expression of CHAT protein] |
CTD |
PMID:18482095 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO |
COMT protein results in increased methylation of caffeic acid |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Malathion results in decreased expression of CRH mRNA] |
CTD |
PMID:25404496 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CTF1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of CTSD protein] |
CTD |
PMID:20391626 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CXCL2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dap |
death-associated protein |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DAP mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DNAJB11 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of DPYSL4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of EDN1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
caffeic acid affects the reaction [Acetaminophen results in increased expression of and affects the localization of EGR1 protein]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of EGR1 mRNA] |
CTD |
PMID:27720869 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ELMO2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G |
Erf |
Ets2 repressor factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of ERF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:80,829,935...80,838,388
Ensembl chr 1:80,829,935...80,838,388
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of F3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fasn |
fatty acid synthase |
decreases expression multiple interactions |
ISO |
caffeic acid results in decreased expression of FASN mRNA [Metformin co-treated with caffeic acid] results in decreased expression of FASN protein |
CTD |
PMID:21870829 PMID:28576465 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flrt2 |
fibronectin leucine rich transmembrane protein 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLRT2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLT4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A mRNA]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of GLB1 protein] |
CTD |
PMID:20391626 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
caffeic acid results in increased expression of GLS protein |
CTD |
PMID:28576465 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein] |
CTD |
PMID:15212457 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] caffeic acid inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:15212457 PMID:27720869 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of GSR protein] caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of GSR mRNA] |
CTD |
PMID:19442820 PMID:21640567 PMID:22036979 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM2 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTP1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of H6PD protein] |
CTD |
PMID:21640567 |
|
NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of HAVCR2 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of HES1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
caffeic acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
caffeic acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of HSP90B1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of HSPE1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IFNG protein caffeic acid inhibits the reaction [Valproic Acid results in increased expression of IFNG protein] |
CTD |
PMID:27378625 PMID:29968957 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL10 protein |
CTD |
PMID:27378625 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL1B protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein] |
CTD |
PMID:27368151 PMID:27720869 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
caffeic acid results in increased expression of IL2 protein |
CTD |
PMID:27378625 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21r |
interleukin 21 receptor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of IL21R mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:180,168,028...180,195,690
Ensembl chr 1:180,168,097...180,195,522
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL4 protein |
CTD |
PMID:27378625 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IL6 mRNA caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL6 protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein] |
CTD |
PMID:21870829 PMID:27368151 PMID:27720869 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of KIF15 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20b |
kinesin family member 20B |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of KIF20B mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Thapsigargin results in increased expression of KIF2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:21472895 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:21472895 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MFN1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases activity |
EXP |
caffeic acid results in increased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
ISO EXP |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [MPO protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MPO protein] caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]; NG-Nitroarginine Methyl Ester inhibits the reaction [caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]] caffeic acid results in decreased activity of MPO protein |
CTD |
PMID:22036979 PMID:24060682 PMID:33301711 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrpl45 |
mitochondrial ribosomal protein L45 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRPL45 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474
|
|
G |
Mrrf |
mitochondrial ribosome recycling factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRRF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[caffeic acid co-treated with Zymosan] results in increased expression of COX2 protein; caffeic acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
increases expression |
ISO |
caffeic acid results in increased expression of NDP mRNA |
CTD |
PMID:19442820 |
|
NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:29968957 PMID:31306686 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
caffeic acid results in increased expression of NOS3 mRNA |
CTD |
PMID:15740983 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOTCH1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of NT5E protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of NT5E protein] |
CTD |
PMID:28465162 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Pdcd10 |
programmed cell death 10 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PDCD10 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
caffeic acid results in increased expression of PIK3R1 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of PLK1 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plk4 |
polo-like kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of PLK4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:123,802,512...123,820,942
Ensembl chr 2:123,802,512...123,820,942
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
caffeic acid results in increased expression of PPARG mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PRDX5 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:19442820 PMID:22036979 PMID:31306686 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTX3 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of RELA protein] |
CTD |
PMID:29968957 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SCD1 protein |
CTD |
PMID:28576465 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of SERPINE1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of SFXN4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:259,976,480...259,998,778
Ensembl chr 1:259,976,481...259,998,754
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC2A2 mRNA |
CTD |
PMID:33493636 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC5A1 mRNA |
CTD |
PMID:33493636 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [SNCA protein binds to SNCA protein] |
CTD |
PMID:20150427 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SREBF1 protein |
CTD |
PMID:28576465 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stk32a |
serine/threonine kinase 32A |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of STK32A mRNA |
CTD |
PMID:19442820 |
|
NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,259,052...35,369,451
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases sulfation |
ISO |
SULT1C2 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of TNF mRNA caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Valproic Acid results in increased expression of TNF protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] |
CTD |
PMID:21870829 PMID:22036979 PMID:27368151 PMID:29968957 PMID:31306686 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects expression multiple interactions |
ISO |
caffeic acid affects the expression of TP53 protein caffeic acid promotes the reaction [Thapsigargin results in decreased expression of TP53 mRNA] |
CTD |
PMID:11522280 PMID:19442820 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of caffeic acid [TYR protein results in increased oxidation of caffeic acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of UBE2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of caffeic acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases secretion |
ISO |
caffeic acid results in decreased secretion of VEGFA protein |
CTD |
PMID:27378625 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of XDH protein] |
CTD |
PMID:22036979 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of AKT1 protein |
CTD |
PMID:24892518 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDH2 protein |
CTD |
PMID:24892518 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK2 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK4 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects expression multiple interactions |
ISO |
ethyl caffeate affects the expression of ERBB2 protein ethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein |
CTD |
PMID:24892518 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
affects expression |
ISO |
ethyl caffeate affects the expression of FGFR1 protein |
CTD |
PMID:24892518 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Ilk |
integrin-linked kinase |
affects expression |
ISO |
ethyl caffeate affects the expression of ILK protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Kdr |
kinase insert domain receptor |
affects expression |
ISO |
ethyl caffeate affects the expression of KDR protein |
CTD |
PMID:24892518 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK1 protein |
CTD |
PMID:24892518 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK3 protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation |
ISO |
ethyl caffeate affects the phosphorylation of RB1 protein |
CTD |
PMID:24892518 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:25481497 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
methyl caffeate results in increased expression of BAX protein |
CTD |
PMID:26415618 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
methyl caffeate binds to and results in decreased expression of BCL2 protein |
CTD |
PMID:26415618 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
methyl caffeate results in increased expression of BID protein |
CTD |
PMID:26415618 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
methyl caffeate results in increased activity of CASP3 protein |
CTD |
PMID:26415618 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
methyl caffeate analog results in increased expression of CDKN1A protein |
CTD |
PMID:25481497 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
methyl caffeate analog results in decreased expression of KDR protein |
CTD |
PMID:25481497 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:25481497 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:25481497 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
affects binding |
ISO |
methyl caffeate binds to MDM2 protein |
CTD |
PMID:26415618 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:25481497 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:25481497 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25481497 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
methyl caffeate binds to and results in increased activity of PARP1 protein |
CTD |
PMID:26415618 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
methyl caffeate analog results in increased expression of TP53 protein |
CTD |
PMID:25481497 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:25481497 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of A2M mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AANAT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ABCA5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
caffeic acid phenethyl ester metabolite results in decreased activity of ABCC1 protein |
CTD |
PMID:15885658 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acan |
aggrecan |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ACAN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ACOT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] |
CTD |
PMID:28363435 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Methotrexate results in increased activity of ADA protein] |
CTD |
PMID:16325979 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam7 |
ADAM metallopeptidase domain 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADAM7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:42,833,796...42,882,201
Ensembl chr15:42,833,796...42,882,201
|
|
G |
Adcy2 |
adenylate cyclase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADCY2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:34,375,639...34,822,237
Ensembl chr 1:34,375,895...34,822,236
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADRA1D mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AGAP2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:62,897,282...62,914,295
Ensembl chr 7:62,897,282...62,914,295
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in decreased expression of AHR protein] |
CTD |
PMID:17204746 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [AIMP1 protein results in increased expression of IL12B mRNA] |
CTD |
PMID:16365417 |
|
NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AKAP9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1B1 protein |
CTD |
PMID:27163852 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1B10 protein |
CTD |
PMID:27163852 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C1 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C2 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C3 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of AKT1 protein |
CTD |
PMID:32125059 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of ALPL protein] caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of ALPL protein] |
CTD |
PMID:18436364 PMID:28363435 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Ankrd17 |
ankyrin repeat domain 17 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of ANKRD17 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr14:17,723,239...17,862,625
Ensembl chr14:17,721,932...17,862,617
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ARRB1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ATF6 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ATF6 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of ATOX1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Axl |
Axl receptor tyrosine kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AXL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:81,265,656...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of BAX mRNA |
CTD |
PMID:24289642 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
decreases phosphorylation |
ISO |
caffeic acid phenethyl ester results in decreased phosphorylation of BCAR1 protein |
CTD |
PMID:10741720 |
|
NCBI chr19:39,679,218...39,713,952
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:34743973 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bgn |
biglycan |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of BGN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of BIRC2 protein |
CTD |
PMID:15291876 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of BIRC3 protein |
CTD |
PMID:15291876 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CACNA1A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CACNA1H mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CAMK2D mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Capn8 |
calpain 8 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CAPN8 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr13:94,252,218...94,316,146
Ensembl chr13:94,253,054...94,316,146
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CAR3 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car4 |
carbonic anhydrase 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CAR4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Casp1 |
caspase 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of CASP1 protein |
CTD |
PMID:15469948 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
decreases activity multiple interactions increases activity |
EXP ISO |
caffeic acid phenethyl ester results in decreased activity of CASP3 protein caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of CASP3 protein]; caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein] caffeic acid phenethyl ester analog results in increased activity of CASP3 protein |
CTD |
PMID:15469948 PMID:18436364 PMID:28363435 PMID:32125059 PMID:34743973 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] |
CTD |
PMID:18436364 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of CASP9 protein] |
CTD |
PMID:34743973 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; caffeic acid phenethyl ester promotes the reaction [Doxorubicin results in increased activity of CAT protein] caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of CAT protein]; caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:14745846 PMID:15369732 PMID:18436364 PMID:23570914 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of CCL2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CCL5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CCNB1 protein |
CTD |
PMID:16085347 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in decreased expression of CCND1 mRNA; caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] |
CTD |
PMID:20420878 PMID:24289642 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [CDK2 protein binds to CCNE1 protein] [Tretinoin co-treated with caffeic acid phenethyl ester] inhibits the reaction [CDK2 protein binds to CCNE1 protein] |
CTD |
PMID:15885897 PMID:16766008 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions increases expression |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD14 mRNA caffeic acid phenethyl ester results in increased expression of CD14 protein caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased expression of CD14 protein] |
CTD |
PMID:16766008 PMID:20360939 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD151 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD86 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CDK1 protein |
CTD |
PMID:16085347 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [CDK2 protein binds to CCNE1 protein] [Tretinoin co-treated with caffeic acid phenethyl ester] inhibits the reaction [CDK2 protein binds to CCNE1 protein] |
CTD |
PMID:15885897 PMID:16766008 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
caffeic acid phenethyl ester results in increased expression of CDKN1A protein [Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of CDKN1A mRNA; caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of CDKN1A protein]; Tretinoin promotes the reaction [caffeic acid phenethyl ester results in increased expression of CDKN1A protein] |
CTD |
PMID:15885897 PMID:16766008 PMID:24289642 PMID:26056802 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP ISO |
caffeic acid phenethyl ester results in increased expression of CDKN1B protein caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of CDKN1B protein] |
CTD |
PMID:15885897 PMID:26056802 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
EXP |
caffeic acid phenethyl ester results in increased expression of CDKN2A protein caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:15885897 PMID:20360939 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Ceacam4 |
CEA cell adhesion molecule 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CEACAM10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:80,376,667...80,382,943
Ensembl chr 1:80,376,648...80,382,915
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
multiple interactions increases expression |
ISO |
Tretinoin promotes the reaction [caffeic acid phenethyl ester results in increased expression of CEBPE protein] |
CTD |
PMID:16766008 |
|
NCBI chr15:28,169,885...28,171,283
Ensembl chr15:28,169,704...28,171,814
|
|
G |
Cers2 |
ceramide synthase 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314
|
|
G |
Cers4 |
ceramide synthase 4 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr12:2,851,784...2,890,244
Ensembl chr12:2,851,784...2,886,828
|
|
G |
Cgm4 |
carcinoembryonic antigen gene family 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CGM4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:77,776,447...77,789,408
Ensembl chr 1:77,776,447...77,789,396
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CHRNE mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530
|
|
G |
Clcn1 |
chloride voltage-gated channel 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of CLCN1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:71,171,949...71,201,483
Ensembl chr 4:71,172,547...71,199,984
|
|
G |
Cldn2 |
claudin 2 |
decreases expression multiple interactions |
ISO |
caffeic acid phenethyl ester results in decreased expression of CLDN2 mRNA; caffeic acid phenethyl ester results in decreased expression of CLDN2 protein Cantharidin inhibits the reaction [caffeic acid phenethyl ester results in decreased expression of CLDN2 protein]; Chloroquine inhibits the reaction [caffeic acid phenethyl ester results in decreased expression of CLDN2 protein]; CLDN2 protein inhibits the reaction [caffeic acid phenethyl ester results in increased susceptibility to and results in increased activity of Doxorubicin] |
CTD |
PMID:29597147 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLDN7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Clic5 |
chloride intracellular channel 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLIC5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:16,710,980...16,813,427
Ensembl chr 9:16,710,980...16,813,427
|
|
G |
Clock |
clock circadian regulator |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLOCK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
ISO |
caffeic acid phenethyl ester results in increased expression of COL18A1 protein |
CTD |
PMID:20433813 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of COX4I2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:141,228,443...141,239,337
Ensembl chr 3:141,228,443...141,239,331
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of COX6A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of COX7A2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein; [caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CSK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CSPG4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CTNNB1 protein |
CTD |
PMID:10783313 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CTSK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctsm |
cathepsin M |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CTSM mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:3,236,848...3,242,265
Ensembl chr17:3,236,859...3,242,265
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CXCR3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYB5A mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of CYBA mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Calcium results in increased secretion of CYCS protein] |
CTD |
PMID:15469948 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP1A2 mRNA caffeic acid phenethyl ester results in decreased expression of CYP1A2 protein |
CTD |
PMID:20360939 PMID:22291063 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2B1 mRNA caffeic acid phenethyl ester results in decreased expression of CYP2B1 protein |
CTD |
PMID:20360939 PMID:22291063 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of CYP2B2 protein |
CTD |
PMID:22291063 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYP2C13 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2E1 mRNA caffeic acid phenethyl ester inhibits the reaction [CYP2E1 protein results in increased hydroxylation of aniline] |
CTD |
PMID:18436364 PMID:20360939 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYP3A18 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr12:8,880,528...8,930,382
Ensembl chr12:8,880,528...8,930,381
|
|
G |
Cyth2 |
cytohesin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CYTH2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:96,284,252...96,291,090
Ensembl chr 1:96,284,252...96,291,092
|
|
G |
Dbn1 |
drebrin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DBN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Deaf1 |
DEAF1 transcription factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of DEAF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DEGS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664
|
|
G |
Degs2 |
delta(4)-desaturase, sphingolipid 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:127,596,063...127,613,293
Ensembl chr 6:127,596,071...127,613,293
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DGKB mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DHFR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of DISC1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Dmrt1 |
doublesex and mab-3 related transcription factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DMRT1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:223,142,859...223,241,333
Ensembl chr 1:223,142,859...223,241,333
|
|
G |
Dnah10 |
dynein, axonemal, heavy chain 10 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DNAH10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:31,823,451...31,946,857
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DNAH5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:78,937,788...79,255,551
Ensembl chr 2:78,937,800...79,254,890
|
|
G |
Dpys |
dihydropyrimidinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DPYS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:70,822,648...70,929,255
Ensembl chr 7:70,835,789...70,929,231
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of DUSP6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
E2f6 |
E2F transcription factor 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of E2F6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:39,592,224...39,608,685
Ensembl chr 6:39,592,228...39,608,683
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ECHS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Oxygen deficiency results in increased expression of EDN1 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Oxygen deficiency results in increased expression of EDN1 protein] |
CTD |
PMID:21926265 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ETS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FABP7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased expression of FAS protein] |
CTD |
PMID:18436364 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased expression of FASL protein] |
CTD |
PMID:18436364 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of FGF15 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of FGF15 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 1:200,056,656...200,059,944
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FGF7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgg |
fibrinogen gamma chain |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of FGG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FMO2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Foxc2 |
forkhead box C2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FOXC2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Foxd1 |
forkhead box D1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FOXD1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978
|
|
G |
Frmd6 |
FERM domain containing 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FRMD6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:89,345,975...89,419,579
Ensembl chr 6:89,346,035...89,419,579
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FTL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fut2 |
fucosyltransferase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FUT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:96,119,549...96,139,567
Ensembl chr 1:96,119,371...96,140,360
|
|
G |
Gas6 |
growth arrest specific 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GAS6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gc |
GC, vitamin D binding protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GC mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GCH1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of GCLC protein] |
CTD |
PMID:23570914 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GDNF mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
EXP |
NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of GFAP protein] |
CTD |
PMID:20836997 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfer |
growth factor, augmenter of liver regeneration |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GFER mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:13,718,489...13,721,782
Ensembl chr10:13,718,489...13,720,869
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ghr |
growth hormone receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GHR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B protein] |
CTD |
PMID:15350541 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GJC2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467
|
|
G |
Gls |
glutaminase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GLS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gnal |
G protein subunit alpha L |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GNAL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599
|
|
G |
Golga2 |
golgin A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GOLGA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GPR19 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GRIK2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GRIK5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GSR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of GSTK1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of GSTP1 protein |
CTD |
PMID:17106925 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of GSTT2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gyg1 |
glycogenin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GYG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:102,611,888...102,653,916
Ensembl chr 2:102,598,496...102,653,797
|
|
G |
H2ac1 |
H2A clustered histone 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of H2AC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:41,171,384...41,171,776
Ensembl chr17:41,135,489...41,172,022
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of HAMP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hdgf |
heparin binding growth factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of HDGF mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:173,370,147...173,379,756
Ensembl chr 2:173,370,465...173,379,747
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of HMGCS2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
caffeic acid phenethyl ester results in increased expression of HMOX1 protein caffeic acid phenethyl ester analog results in increased expression of HMOX1 mRNA; caffeic acid phenethyl ester analog results in increased expression of HMOX1 protein; caffeic acid phenethyl ester results in increased expression of HMOX1 mRNA; caffeic acid phenethyl ester results in increased expression of HMOX1 protein caffeic acid phenethyl ester inhibits the reaction [Fructose results in increased expression of HMOX1 protein]; caffeic acid phenethyl ester inhibits the reaction [Streptozocin results in increased expression of HMOX1 protein] |
CTD |
PMID:20226179 PMID:20950636 PMID:21472898 PMID:23942037 PMID:24508943 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpr |
heterogeneous nuclear ribonucleoprotein R |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HNRNPR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867
|
|
G |
Hpcal4 |
hippocalcin-like 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HPCAL4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPB1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb2 |
heat shock protein family B (small) member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:51,093,267...51,094,864
Ensembl chr 8:51,081,342...51,094,533
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Idh3b |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 3:117,481,845...117,486,909
Ensembl chr 3:117,481,845...117,486,982
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IDO1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:67,430,684...67,442,459
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in decreased expression of IFNG protein; caffeic acid phenethyl ester inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 PMID:24289642 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igbp1 |
immunoglobulin binding protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IGBP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:65,582,832...65,605,078
Ensembl chr X:65,582,821...65,606,049
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [AIMP1 protein results in increased expression of IL12B mRNA] |
CTD |
PMID:16365417 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL18 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL1A mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IL1B mRNA; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B protein] caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein] |
CTD |
PMID:15350541 PMID:20360939 PMID:34743973 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of IL6 protein] |
CTD |
PMID:34743973 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insrr |
insulin receptor-related receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of INSRR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:173,255,335...173,274,800
Ensembl chr 2:173,255,414...173,274,800
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of IP6K2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of IRS1 mRNA |
CTD |
PMID:21467634 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased expression of ITGAM protein] caffeic acid phenethyl ester results in increased expression of ITGAM protein |
CTD |
PMID:16766008 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in increased expression of JUN mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kalrn |
kalirin, RhoGEF kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KALRN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:66,198,155...66,803,166
Ensembl chr11:66,198,173...66,797,610
|
|
G |
Kcng3 |
potassium voltage-gated channel modifier subfamily G member 3 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of KCNG3 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 6:11,051,311...11,099,264
Ensembl chr 6:11,051,134...11,099,264
|
|
G |
Kcnh5 |
potassium voltage-gated channel subfamily H member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNH5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:93,615,174...93,908,107
Ensembl chr 6:93,624,529...93,908,107
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of KCNJ2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:96,060,849...96,071,401
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnmb2 |
potassium calcium-activated channel subfamily M regulatory beta subunit 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNMB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:114,670,027...114,975,406
Ensembl chr 2:114,935,976...114,975,173
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNQ2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Kcnt2 |
potassium sodium-activated channel subfamily T member 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of KCNT2 mRNA |
CTD |
PMID:26100633 |
|
NCBI chr13:51,664,129...52,059,209
Ensembl chr13:51,664,686...52,056,987
|
|
G |
Kif6 |
kinesin family member 6 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of KIF6 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 9:11,076,203...11,373,205
Ensembl chr 9:11,072,824...11,373,006
|
|
G |
Klhl17 |
kelch-like family member 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KLHL17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:166,813,482...166,819,949
Ensembl chr 5:166,814,110...166,818,925
|
|
G |
Lalba |
lactalbumin, alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LALBA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:129,625,752...129,628,022
Ensembl chr 7:129,625,535...129,628,061
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of LEP mRNA; caffeic acid phenethyl ester results in decreased expression of LEP protein |
CTD |
PMID:21467634 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Leprot |
leptin receptor overlapping transcript |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LEPROT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:116,289,843...116,301,951
Ensembl chr 5:116,289,822...116,301,988
|
|
G |
Lgi1 |
leucine-rich, glioma inactivated 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LGI1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:236,043,376...236,084,270
Ensembl chr 1:236,042,954...236,084,616
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LMNA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lrrc15 |
leucine rich repeat containing 15 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LRRC15 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:70,469,775...70,484,268
Ensembl chr11:70,469,804...70,484,267
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of MAPK1 protein |
CTD |
PMID:32125059 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MAPK14 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of MAPK3 protein |
CTD |
PMID:32125059 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ME1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of MFN2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of MFN2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions |
EXP |
caffeic acid phenethyl ester results in decreased activity of MMP2 protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP2 protein] |
CTD |
PMID:20836997 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of MMP3 mRNA caffeic acid phenethyl ester inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MMP3 protein] |
CTD |
PMID:20360939 PMID:34791780 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions decreases activity |
ISO EXP |
caffeic acid phenethyl ester results in decreased expression of MMP9 protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP9 protein] |
CTD |
PMID:20433813 PMID:20836997 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Doxorubicin results in increased activity of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Isoproterenol results in increased activity of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:15369732 PMID:20693123 PMID:21472898 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mprip |
myosin phosphatase Rho interacting protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MPRIP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:44,453,929...44,569,442
Ensembl chr10:44,453,929...44,569,118
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MSX2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mterf1 |
mitochondrial transcription termination factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MTERF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:30,226,345...30,233,402
Ensembl chr 4:30,226,343...30,233,584
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of MTUS1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr16:51,202,497...51,347,791
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MUC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Mug1 |
murinoglobulin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PZP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MXI1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myo9a |
myosin IXA |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of MYO9A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:60,149,234...60,348,726
Ensembl chr 8:60,149,234...60,350,514
|
|
G |
Nat8b |
N-acetyltransferase 8B |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NAT8B mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:118,359,445...118,364,351
Ensembl chr 4:118,359,443...118,363,563
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NCAM1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Ndufa10l1 |
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10-like 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NDUFA10L1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:59,879,819...59,881,252
Ensembl chr 6:59,879,312...59,881,241
|
|
G |
Neo1 |
neogenin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NEO1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:59,273,860...59,426,486
Ensembl chr 8:59,275,569...59,430,348
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein] caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:17204746 PMID:23570914 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfia |
nuclear factor I/A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NFIA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased activity of [NFKB1 protein binds to RELA protein]] caffeic acid phenethyl ester results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:11259437 PMID:16052512 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of NFKB2 protein] |
CTD |
PMID:20420878 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation |
EXP |
caffeic acid phenethyl ester results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:20836997 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfya |
nuclear transcription factor Y subunit alpha |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of NFYA mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898
|
|
G |
Ngf |
nerve growth factor |
increases expression |
EXP |
caffeic acid phenethyl ester results in increased expression of NGF protein |
CTD |
PMID:20836997 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression multiple interactions affects response to substance |
EXP |
caffeic acid phenethyl ester results in increased expression of NGFR protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP2 protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP9 protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of GFAP protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of RHOB protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of S100B protein] NGFR protein affects the susceptibility to caffeic acid phenethyl ester |
CTD |
PMID:20836997 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NOG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of NOS2 protein |
CTD |
PMID:15469948 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NOTCH2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of NOX4 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of NOX4 protein]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of NOX4 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of NOX4 protein] |
CTD |
PMID:24224404 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of NR0B2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of NR0B2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in decreased expression of INS1 protein; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Citric Acid; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Fumarates; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Ketoglutaric Acids; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of malic acid; [NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nrtn |
neurturin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NRTN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102
|
|
G |
Nup88 |
nucleoporin 88 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of NUP88 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:55,667,903...55,692,249
Ensembl chr10:55,667,906...55,692,257
|
|
G |
Odf1 |
outer dense fiber of sperm tails 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ODF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:69,377,427...69,389,662
Ensembl chr 7:69,380,116...69,389,664
|
|
G |
Olig1 |
oligodendrocyte transcription factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of OLIG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:30,514,379...30,516,521
Ensembl chr11:30,514,379...30,516,521
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of OLR1 protein] |
CTD |
PMID:24145059 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of OPA1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Pacs2 |
phosphofurin acidic cluster sorting protein 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:132,096,992...132,156,702
Ensembl chr 6:132,096,901...132,154,583
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PARD3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:55,080,282...55,630,111
Ensembl chr19:55,080,282...55,629,778
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased activity of PC protein; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased activity of PC protein] |
CTD |
PMID:28223344 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PCK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PCSK1N mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:14,580,036...14,583,478
Ensembl chr X:14,580,038...14,583,566
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of PCSK2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pcsk6 |
proprotein convertase subtilisin/kexin type 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PCSK6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:119,428,978...119,627,626
Ensembl chr 1:119,429,265...119,627,596
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PDGFRB mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:54,500,002...54,538,843
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Per3 |
period circadian regulator 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PER3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607
|
|
G |
Pfkp |
phosphofructokinase, platelet |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PFKP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Phkg2 |
phosphorylase kinase catalytic subunit gamma 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of PHKG2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:182,184,362...182,197,124
Ensembl chr 1:182,184,650...182,197,124
|
|
G |
Pias2 |
protein inhibitor of activated STAT, 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PIAS2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:70,608,034...70,714,295
Ensembl chr18:70,607,665...70,710,033
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PLCG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Plekha5 |
pleckstrin homology domain containing A5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PLEKHA5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of POLD1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of POLG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of PPARG mRNA |
CTD |
PMID:21467634 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PPP2R2A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Ppp4c |
protein phosphatase 4, catalytic subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PPP4C mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:181,392,899...181,399,703
Ensembl chr 1:181,392,923...181,399,659
|
|
G |
Prep |
prolyl endopeptidase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PREP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:48,556,211...48,653,165
Ensembl chr20:48,556,280...48,654,466
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKACA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKAR2A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKCE mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prok2 |
prokineticin 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of PROK2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385
|
|
G |
Prom1 |
prominin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PROM1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Prss3 |
serine protease 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRSS3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:70,203,088...70,206,562
Ensembl chr 4:70,203,088...70,206,562
|
|
G |
Psma7 |
proteasome 20S subunit alpha 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PSMA7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:167,137,279...167,143,626
Ensembl chr 3:167,137,263...167,143,672
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
caffeic acid phenethyl ester results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:10741720 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PTPN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RAMP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity increases expression multiple interactions |
ISO |
caffeic acid phenethyl ester results in increased activity of RARA protein caffeic acid phenethyl ester results in increased expression of RARA mRNA; caffeic acid phenethyl ester results in increased expression of RARA protein [Tretinoin co-treated with caffeic acid phenethyl ester] results in increased expression of RARA mRNA; [Tretinoin co-treated with caffeic acid phenethyl ester] results in increased expression of RARA protein; caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased activity of RARA protein] |
CTD |
PMID:16766008 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of RB1 protein modified form |
CTD |
PMID:15885897 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of RCAN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Paclitaxel results in increased activity of RELA protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased activity of RELA protein]; caffeic acid phenethyl ester results in decreased activity of [NFKB1 protein binds to RELA protein] caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11259437 PMID:15291876 PMID:16052512 PMID:26562779 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rem2 |
RRAD and GEM like GTPase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of REM2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:27,933,950...27,938,429
Ensembl chr15:27,933,950...27,938,429
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RET mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of RETN protein |
CTD |
PMID:21467634 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rfc1 |
replication factor C subunit 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RFC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:42,966,279...43,041,372
Ensembl chr14:42,966,324...43,041,370
|
|
G |
Rgs6 |
regulator of G-protein signaling 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RGS6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:102,264,451...102,796,311
Ensembl chr 6:102,264,447...102,824,753
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions increases expression |
EXP |
NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of RHOB protein] |
CTD |
PMID:20836997 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rpe65 |
retinoid isomerohydrolase RPE65 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPE65 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403
|
|
G |
Rph3a |
rabphilin 3A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPH3A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:35,542,389...35,618,901
Ensembl chr12:35,542,728...35,617,592
|
|
G |
Rpl26 |
ribosomal protein L26 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of RPL26 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966
|
|
G |
Rps3a |
ribosomal protein S3a |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPS3A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:171,524,685...171,529,054
Ensembl chr 2:171,524,500...171,529,055
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of RPS6KA2 protein]; caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of RPS6KA2 protein] |
CTD |
PMID:17204746 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
Rps9 |
ribosomal protein S9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPS9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:65,511,723...65,515,121
Ensembl chr 1:65,511,723...65,515,123
|
|
G |
RT1-A3 |
RT1 class I, locus A3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-A3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:4,847,518...4,851,344
|
|
G |
RT1-N1 |
RT1 class Ib, locus N1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-N1 mRNA |
CTD |
PMID:20360939 |
|
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-S3 mRNA; [Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of RT1-S3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:2,670,654...2,675,411
Ensembl chr20:2,670,709...2,675,411
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein] |
CTD |
PMID:28363435 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
S100b |
S100 calcium binding protein B |
increases expression multiple interactions |
EXP |
caffeic acid phenethyl ester results in increased expression of S100B protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of S100B protein] |
CTD |
PMID:20836997 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scaper |
S-phase cyclin A-associated protein in the ER |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SCAPER mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:55,932,717...56,332,222
Ensembl chr 8:55,933,306...56,332,122
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SCD1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of SCNN1G mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of SDC4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Sds |
serine dehydratase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SDS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:36,083,226...36,090,540
Ensembl chr12:36,083,229...36,088,203
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinb5 |
serpin family B member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINB5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756
|
|
G |
Serpinf1 |
serpin family F member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SIRT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Slc12a8 |
solute carrier family 12, member 8 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC12A8 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:67,116,876...67,266,548
Ensembl chr11:67,116,877...67,266,834
|
|
G |
Slc14a2 |
solute carrier family 14 member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC14A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:71,612,460...72,039,462
Ensembl chr18:71,612,460...71,792,968
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC17A8 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC1A5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc45a1 |
solute carrier family 45, member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC45A1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:161,105,137...161,129,375
Ensembl chr 5:161,105,235...161,129,303
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC4A2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc51a |
solute carrier family 51 subunit alpha |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51A mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51A mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51B mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51B mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Smpd4 |
sphingomyelin phosphodiesterase 4 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr11:83,362,534...83,386,257
Ensembl chr11:83,362,534...83,386,250
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of SND1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SOAT1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of SOD1 protein] |
CTD |
PMID:22692362 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SOX10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:110,725,274...110,735,544
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Spa17 |
sperm autoantigenic protein 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SPA17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:37,307,432...37,318,645
Ensembl chr 8:37,307,557...37,318,639
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SPHK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Sptlc2 |
serine palmitoyltransferase, long chain base subunit 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:106,948,681...107,031,584
Ensembl chr 6:106,950,949...107,031,542
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cyclosporine results in increased phosphorylation of STAT3 protein] caffeic acid phenethyl ester analog affects the expression of and affects the phosphorylation of STAT3 protein |
CTD |
PMID:22155090 PMID:32125059 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Strn |
striatin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of STRN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:16,335,265...16,422,159
Ensembl chr 6:16,335,358...16,417,083
|
|
G |
Stx2 |
syntaxin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of STX2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:27,678,744...27,714,751
Ensembl chr12:27,689,819...27,714,751
|
|
G |
Tec |
tec protein tyrosine kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TEC mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557
|
|
G |
Tg |
thyroglobulin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TGFB2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgm4 |
transglutaminase 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TGM4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:122,689,429...122,726,463
Ensembl chr 8:122,689,429...122,726,463
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TH mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tk1 |
thymidine kinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tkt |
transketolase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TKT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of TLR4 protein] |
CTD |
PMID:34743973 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmod2 |
tropomodulin 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of TMOD2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:76,316,736...76,366,003
Ensembl chr 8:76,325,667...76,365,720
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased activity of RELA protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of TNF protein] caffeic acid phenethyl ester inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased expression of TNF protein] caffeic acid phenethyl ester results in decreased expression of TNF protein caffeic acid phenethyl ester inhibits the reaction [Fructose results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Streptozocin results in increased expression of TNF protein] |
CTD |
PMID:10757128 PMID:11259437 PMID:15291876 PMID:16085347 PMID:16271621 PMID:21467634 PMID:21472898 PMID:24224404 PMID:24508943 PMID:26562779 PMID:34743973 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:24289642 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA] |
CTD |
PMID:28363435 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:28363435 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of TNNT1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:69,306,362...69,316,721
Ensembl chr 1:69,306,362...69,316,721
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of TP53 protein] caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] |
CTD |
PMID:17204746 PMID:20360939 PMID:22692362 PMID:26056802 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trim17 |
tripartite motif-containing 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TRIM17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:43,743,111...43,750,929
Ensembl chr10:43,740,604...43,750,919
|
|
G |
Ttn |
titin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TTN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741
|
|
G |
Txnl1 |
thioredoxin-like 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TXNL1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:57,125,362...57,155,167
Ensembl chr18:57,125,369...57,165,266
|
|
G |
Tyr |
tyrosinase |
multiple interactions affects response to substance increases oxidation |
ISO |
[TYR protein affects the susceptibility to caffeic acid phenethyl ester] which affects the abundance of Glutathione; [TYR protein affects the susceptibility to caffeic acid phenethyl ester] which affects the abundance of Reactive Oxygen Species; ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid]; ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; ethylenediamine inhibits the reaction [TYR protein results in increased oxidation of caffeic acid phenethyl ester]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [TYR protein results in increased oxidation of caffeic acid phenethyl ester]; TYR protein results in increased metabolism of and results in increased susceptibility to caffeic acid phenethyl ester [TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid; [TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD; TYR protein results in increased oxidation of caffeic acid phenethyl ester |
CTD |
PMID:20685355 PMID:21458432 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Vamp8 |
vesicle-associated membrane protein 8 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VAMP8 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:104,442,383...104,452,884
Ensembl chr 4:104,442,393...104,452,897
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:16271621 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VCPIP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:9,534,247...9,560,889
Ensembl chr 5:9,534,129...9,562,040
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
|